Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

Showing products 1–24 of 30. More products

DEFERASIROX

All strengths: General benefit; same patient cost rules

Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysPatient pays: program not supplied; amount cannot be determined.

Other products in the same Health Canada class (V03AC) — coverage varies; not interchangeable

  • Deferiprone (Ferriprox): not a benefit

Apo-Deferasirox (Type J) · DIN 02485265 · 90mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Deferasirox (Type J) · DIN 02485265 Manufacturer: Apotex Inc.; listing date 2019-07-31 Health Canada: Marketed since 2019-05-29 · brand APO-DEFERASIROX (TYPE J) · ATC V03AC03 DEFERASIROX · form Tablet · route Oral · ingredients DEFERASIROX 90 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Deferasirox (Type J): Formulary list price $2.6303/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.6303 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97553 · Verify on the e-Formulary ↗ (DIN 02485265)

Source record
DIN 02485265: Apo-Deferasirox (Type J) Raw flags: sec3=Y Item: 640000021; group id 700; item number 1727; lccId None; manufacturer id APX Source form: Tab; strength: 90mg Recorded listing: General benefit Source prices (unrounded): $2.6303; ministry $2.6303 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02485265 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97553
Interchangeable products
Auro-Deferasirox (Type J) · DIN 02527774 · $2.6303 Jadenu · DIN 02452219 · $2.6303 Jamp Deferasirox (Type J) · DIN 02549832 · $2.6303 PMS-Deferasirox (Type J) · DIN 02528290 · $2.6303 Sandoz Deferasirox (Type J) · DIN 02489899 · $2.6303 Taro-Deferasirox (Type J) · DIN 02507315 · $2.6303
Shortage status: resolved shortage (ended 2021-01-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02485265
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Deferasirox (Type J) · DIN 02527774 · 90mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Deferasirox (Type J) · DIN 02527774 Manufacturer: Auro Pharma Inc.; listing date 2025-02-28 Health Canada: Marketed since 2024-08-14 · brand AURO-DEFERASIROX (TYPE J) · ATC V03AC03 DEFERASIROX · form Tablet · route Oral · ingredients DEFERASIROX 90 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Deferasirox (Type J): Formulary list price $2.6303/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.6303 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101695 · Verify on the e-Formulary ↗ (DIN 02527774)

Source record
DIN 02527774: Auro-Deferasirox (Type J) Raw flags: sec3=Y Item: 640000021; group id 700; item number 1727; lccId None; manufacturer id AUR Source form: Tab; strength: 90mg Recorded listing: General benefit Source prices (unrounded): $2.6303; ministry $2.6303 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02527774 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101695
Interchangeable products
Apo-Deferasirox (Type J) · DIN 02485265 · $2.6303 Jadenu · DIN 02452219 · $2.6303 Jamp Deferasirox (Type J) · DIN 02549832 · $2.6303 PMS-Deferasirox (Type J) · DIN 02528290 · $2.6303 Sandoz Deferasirox (Type J) · DIN 02489899 · $2.6303 Taro-Deferasirox (Type J) · DIN 02507315 · $2.6303
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02527774
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jadenu · DIN 02452219 · 90mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jadenu · DIN 02452219 Manufacturer: Novartis Pharma Canada Inc.; listing date 2019-07-31 Health Canada: Marketed since 2016-03-24 · brand JADENU · ATC V03AC03 DEFERASIROX · form Tablet · route Oral · ingredients DEFERASIROX 90 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $2.6303 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93864 · Verify on the e-Formulary ↗ (DIN 02452219)

Source record
DIN 02452219: Jadenu Raw flags: sec3=Y Item: 640000021; group id 700; item number 1727; lccId None; manufacturer id NOV Source form: Tab; strength: 90mg Recorded listing: General benefit Source prices (unrounded): $11.2719; ministry $2.6303 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02452219 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93864
Interchangeable products
Apo-Deferasirox (Type J) · DIN 02485265 · $2.6303 Auro-Deferasirox (Type J) · DIN 02527774 · $2.6303 Jamp Deferasirox (Type J) · DIN 02549832 · $2.6303 PMS-Deferasirox (Type J) · DIN 02528290 · $2.6303 Sandoz Deferasirox (Type J) · DIN 02489899 · $2.6303 Taro-Deferasirox (Type J) · DIN 02507315 · $2.6303
Shortage status: anticipated shortage (last updated 2026-08-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02452219
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Deferasirox (Type J) · DIN 02549832 · 90mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Deferasirox (Type J) · DIN 02549832 Manufacturer: Jamp Pharma Corporation; listing date 2026-07-31 Health Canada: Marketed since 2026-06-15 · brand JAMP DEFERASIROX (TYPE J) · ATC V03AC03 DEFERASIROX · form Tablet · route Oral · ingredients DEFERASIROX 90 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Deferasirox (Type J): Formulary list price $2.6303/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.6303 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103865 · Verify on the e-Formulary ↗ (DIN 02549832)

Source record
DIN 02549832: Jamp Deferasirox (Type J) Raw flags: sec3=Y Item: 640000021; group id 700; item number 1727; lccId None; manufacturer id JPC Source form: Tab; strength: 90mg Recorded listing: General benefit Source prices (unrounded): $2.6303; ministry $2.6303 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02549832 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103865
Interchangeable products
Apo-Deferasirox (Type J) · DIN 02485265 · $2.6303 Auro-Deferasirox (Type J) · DIN 02527774 · $2.6303 Jadenu · DIN 02452219 · $2.6303 PMS-Deferasirox (Type J) · DIN 02528290 · $2.6303 Sandoz Deferasirox (Type J) · DIN 02489899 · $2.6303 Taro-Deferasirox (Type J) · DIN 02507315 · $2.6303
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02549832
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Deferasirox (Type J) · DIN 02528290 · 90mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Deferasirox (Type J) · DIN 02528290 Manufacturer: Pharmascience Inc.; listing date 2022-10-31 Health Canada: Marketed since 2022-08-31 · brand PMS-DEFERASIROX (TYPE J) · ATC V03AC03 DEFERASIROX · form Tablet · route Oral · ingredients DEFERASIROX 90 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Deferasirox (Type J): Formulary list price $2.6303/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.6303 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101753 · Verify on the e-Formulary ↗ (DIN 02528290)

Source record
DIN 02528290: PMS-Deferasirox (Type J) Raw flags: sec3=Y Item: 640000021; group id 700; item number 1727; lccId None; manufacturer id PMS Source form: Tab; strength: 90mg Recorded listing: General benefit Source prices (unrounded): $2.6303; ministry $2.6303 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02528290 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101753
Interchangeable products
Apo-Deferasirox (Type J) · DIN 02485265 · $2.6303 Auro-Deferasirox (Type J) · DIN 02527774 · $2.6303 Jadenu · DIN 02452219 · $2.6303 Jamp Deferasirox (Type J) · DIN 02549832 · $2.6303 Sandoz Deferasirox (Type J) · DIN 02489899 · $2.6303 Taro-Deferasirox (Type J) · DIN 02507315 · $2.6303
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02528290
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Deferasirox (Type J) · DIN 02489899 · 90mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Deferasirox (Type J) · DIN 02489899 Manufacturer: Sandoz Canada Inc.; listing date 2021-07-30 Health Canada: Marketed since 2021-04-19 · brand SANDOZ DEFERASIROX (TYPE J) · ATC V03AC03 DEFERASIROX · form Tablet · route Oral · ingredients DEFERASIROX 90 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Deferasirox (Type J): Formulary list price $2.6303/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.6303 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97996 · Verify on the e-Formulary ↗ (DIN 02489899)

Source record
DIN 02489899: Sandoz Deferasirox (Type J) Raw flags: sec3=Y Item: 640000021; group id 700; item number 1727; lccId None; manufacturer id SDZ Source form: Tab; strength: 90mg Recorded listing: General benefit Source prices (unrounded): $2.6303; ministry $2.6303 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02489899 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97996
Interchangeable products
Apo-Deferasirox (Type J) · DIN 02485265 · $2.6303 Auro-Deferasirox (Type J) · DIN 02527774 · $2.6303 Jadenu · DIN 02452219 · $2.6303 Jamp Deferasirox (Type J) · DIN 02549832 · $2.6303 PMS-Deferasirox (Type J) · DIN 02528290 · $2.6303 Taro-Deferasirox (Type J) · DIN 02507315 · $2.6303
Shortage status: resolved shortage (ended 2025-04-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489899
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Deferasirox (Type J) · DIN 02507315 · 90mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Deferasirox (Type J) · DIN 02507315 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2021-03-29 Health Canada: Marketed since 2021-03-04 · brand TARO-DEFERASIROX (TYPE J) · ATC V03AC03 DEFERASIROX · form Tablet · route Oral · ingredients DEFERASIROX 90 MG · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Deferasirox (Type J): Formulary list price $2.6303/unit (unit not stated in source; not the patient's cost)

Ministry pays: $2.6303 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99672 · Verify on the e-Formulary ↗ (DIN 02507315)

Source record
DIN 02507315: Taro-Deferasirox (Type J) Raw flags: sec3=Y Item: 640000021; group id 700; item number 1727; lccId None; manufacturer id TAR Source form: Tab; strength: 90mg Recorded listing: General benefit Source prices (unrounded): $2.6303; ministry $2.6303 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02507315 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99672
Interchangeable products
Apo-Deferasirox (Type J) · DIN 02485265 · $2.6303 Auro-Deferasirox (Type J) · DIN 02527774 · $2.6303 Jadenu · DIN 02452219 · $2.6303 Jamp Deferasirox (Type J) · DIN 02549832 · $2.6303 PMS-Deferasirox (Type J) · DIN 02528290 · $2.6303 Sandoz Deferasirox (Type J) · DIN 02489899 · $2.6303
Shortage status: resolved shortage (ended 2025-12-12); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02507315
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Deferasirox · DIN 02461544 · 125mg · tablet for suspension

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Deferasirox · DIN 02461544 Manufacturer: Apotex Inc.; listing date 2017-08-30 Health Canada: Marketed since 2017-06-26 · brand APO-DEFERASIROX · ATC V03AC03 DEFERASIROX · form Tablet for suspension · route Oral · ingredients DEFERASIROX 125 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Deferasirox: Formulary list price $5.2408/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.2408 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94918 · Verify on the e-Formulary ↗ (DIN 02461544)

Source record
DIN 02461544: Apo-Deferasirox Raw flags: sec3=Y Item: 640000013; group id 700; item number 1730; lccId None; manufacturer id APX Source form: Tab for Susp; strength: 125mg Recorded listing: General benefit Source prices (unrounded): $5.2408; ministry $5.2408 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02461544 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94918
Interchangeable products
Exjade · DIN 02287420 · $5.2408 Sandoz Deferasirox · DIN 02464454 · $5.2408
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02461544
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Exjade · DIN 02287420 · 125mg · tablet for suspension

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Exjade · DIN 02287420 Manufacturer: Novartis Pharma Canada Inc.; listing date 2017-08-30 Health Canada: Marketed since 2006-11-10 · brand EXJADE · ATC V03AC03 DEFERASIROX · form Tablet for suspension · route Oral · ingredients DEFERASIROX 125 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $5.2408 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77283 · Verify on the e-Formulary ↗ (DIN 02287420)

Source record
DIN 02287420: Exjade Raw flags: sec3=Y Item: 640000013; group id 700; item number 1730; lccId None; manufacturer id NOV Source form: Tab for Susp; strength: 125mg Recorded listing: General benefit Source prices (unrounded): $11.5231; ministry $5.2408 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02287420 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77283
Interchangeable products
Apo-Deferasirox · DIN 02461544 · $5.2408 Sandoz Deferasirox · DIN 02464454 · $5.2408
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02287420
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Deferasirox · DIN 02464454 · 125mg · tablet for suspension

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Deferasirox · DIN 02464454 Manufacturer: Sandoz Canada Inc.; listing date 2017-08-30 Health Canada: Marketed since 2017-07-04 · brand SANDOZ DEFERASIROX · ATC V03AC03 DEFERASIROX · form Tablet for suspension · route Oral · ingredients DEFERASIROX 125 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Deferasirox: Formulary list price $5.2408/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.2408 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95259 · Verify on the e-Formulary ↗ (DIN 02464454)

Source record
DIN 02464454: Sandoz Deferasirox Raw flags: sec3=Y Item: 640000013; group id 700; item number 1730; lccId None; manufacturer id SDZ Source form: Tab for Susp; strength: 125mg Recorded listing: General benefit Source prices (unrounded): $5.2408; ministry $5.2408 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02464454 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95259
Interchangeable products
Apo-Deferasirox · DIN 02461544 · $5.2408 Exjade · DIN 02287420 · $5.2408
Shortage status: resolved shortage (ended 2022-01-17); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02464454
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Deferasirox (Type J) · DIN 02485273 · 180mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Deferasirox (Type J) · DIN 02485273 Manufacturer: Apotex Inc.; listing date 2019-07-31 Health Canada: Marketed since 2019-05-29 · brand APO-DEFERASIROX (TYPE J) · ATC V03AC03 DEFERASIROX · form Tablet · route Oral · ingredients DEFERASIROX 180 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Deferasirox (Type J): Formulary list price $5.2610/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.2610 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97554 · Verify on the e-Formulary ↗ (DIN 02485273)

Source record
DIN 02485273: Apo-Deferasirox (Type J) Raw flags: sec3=Y Item: 640000022; group id 700; item number 1728; lccId None; manufacturer id APX Source form: Tab; strength: 180mg Recorded listing: General benefit Source prices (unrounded): $5.2610; ministry $5.2610 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02485273 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97554
Interchangeable products
Auro-Deferasirox (Type J) · DIN 02527782 · $5.2610 Jadenu · DIN 02452227 · $5.2610 Jamp Deferasirox (Type J) · DIN 02549840 · $5.2610 PMS-Deferasirox (Type J) · DIN 02528304 · $5.2610 Sandoz Deferasirox (Type J) · DIN 02489902 · $5.2610 Taro-Deferasirox (Type J) · DIN 02507323 · $5.2610
Shortage status: resolved shortage (ended 2025-02-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02485273
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Deferasirox (Type J) · DIN 02527782 · 180mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Deferasirox (Type J) · DIN 02527782 Manufacturer: Auro Pharma Inc.; listing date 2025-02-28 Health Canada: Marketed since 2024-08-14 · brand AURO-DEFERASIROX (TYPE J) · ATC V03AC03 DEFERASIROX · form Tablet · route Oral · ingredients DEFERASIROX 180 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Deferasirox (Type J): Formulary list price $5.2610/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.2610 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101696 · Verify on the e-Formulary ↗ (DIN 02527782)

Source record
DIN 02527782: Auro-Deferasirox (Type J) Raw flags: sec3=Y Item: 640000022; group id 700; item number 1728; lccId None; manufacturer id AUR Source form: Tab; strength: 180mg Recorded listing: General benefit Source prices (unrounded): $5.2610; ministry $5.2610 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02527782 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101696
Interchangeable products
Apo-Deferasirox (Type J) · DIN 02485273 · $5.2610 Jadenu · DIN 02452227 · $5.2610 Jamp Deferasirox (Type J) · DIN 02549840 · $5.2610 PMS-Deferasirox (Type J) · DIN 02528304 · $5.2610 Sandoz Deferasirox (Type J) · DIN 02489902 · $5.2610 Taro-Deferasirox (Type J) · DIN 02507323 · $5.2610
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02527782
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jadenu · DIN 02452227 · 180mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jadenu · DIN 02452227 Manufacturer: Novartis Pharma Canada Inc.; listing date 2019-07-31 Health Canada: Marketed since 2016-03-24 · brand JADENU · ATC V03AC03 DEFERASIROX · form Tablet · route Oral · ingredients DEFERASIROX 180 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $5.2610 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93865 · Verify on the e-Formulary ↗ (DIN 02452227)

Source record
DIN 02452227: Jadenu Raw flags: sec3=Y Item: 640000022; group id 700; item number 1728; lccId None; manufacturer id NOV Source form: Tab; strength: 180mg Recorded listing: General benefit Source prices (unrounded): $22.5442; ministry $5.2610 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02452227 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93865
Interchangeable products
Apo-Deferasirox (Type J) · DIN 02485273 · $5.2610 Auro-Deferasirox (Type J) · DIN 02527782 · $5.2610 Jamp Deferasirox (Type J) · DIN 02549840 · $5.2610 PMS-Deferasirox (Type J) · DIN 02528304 · $5.2610 Sandoz Deferasirox (Type J) · DIN 02489902 · $5.2610 Taro-Deferasirox (Type J) · DIN 02507323 · $5.2610
Shortage status: anticipated shortage (last updated 2026-09-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02452227
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Deferasirox (Type J) · DIN 02549840 · 180mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Deferasirox (Type J) · DIN 02549840 Manufacturer: Jamp Pharma Corporation; listing date 2026-07-31 Health Canada: Marketed since 2026-06-15 · brand JAMP DEFERASIROX (TYPE J) · ATC V03AC03 DEFERASIROX · form Tablet · route Oral · ingredients DEFERASIROX 180 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Deferasirox (Type J): Formulary list price $5.2610/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.2610 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103866 · Verify on the e-Formulary ↗ (DIN 02549840)

Source record
DIN 02549840: Jamp Deferasirox (Type J) Raw flags: sec3=Y Item: 640000022; group id 700; item number 1728; lccId None; manufacturer id JPC Source form: Tab; strength: 180mg Recorded listing: General benefit Source prices (unrounded): $5.2610; ministry $5.2610 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02549840 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103866
Interchangeable products
Apo-Deferasirox (Type J) · DIN 02485273 · $5.2610 Auro-Deferasirox (Type J) · DIN 02527782 · $5.2610 Jadenu · DIN 02452227 · $5.2610 PMS-Deferasirox (Type J) · DIN 02528304 · $5.2610 Sandoz Deferasirox (Type J) · DIN 02489902 · $5.2610 Taro-Deferasirox (Type J) · DIN 02507323 · $5.2610
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02549840
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Deferasirox (Type J) · DIN 02528304 · 180mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Deferasirox (Type J) · DIN 02528304 Manufacturer: Pharmascience Inc.; listing date 2022-11-30 Health Canada: Marketed since 2022-09-30 · brand PMS-DEFERASIROX (TYPE J) · ATC V03AC03 DEFERASIROX · form Tablet · route Oral · ingredients DEFERASIROX 180 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Deferasirox (Type J): Formulary list price $5.2610/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.2610 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101754 · Verify on the e-Formulary ↗ (DIN 02528304)

Source record
DIN 02528304: PMS-Deferasirox (Type J) Raw flags: sec3=Y Item: 640000022; group id 700; item number 1728; lccId None; manufacturer id PMS Source form: Tab; strength: 180mg Recorded listing: General benefit Source prices (unrounded): $5.2610; ministry $5.2610 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02528304 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101754
Interchangeable products
Apo-Deferasirox (Type J) · DIN 02485273 · $5.2610 Auro-Deferasirox (Type J) · DIN 02527782 · $5.2610 Jadenu · DIN 02452227 · $5.2610 Jamp Deferasirox (Type J) · DIN 02549840 · $5.2610 Sandoz Deferasirox (Type J) · DIN 02489902 · $5.2610 Taro-Deferasirox (Type J) · DIN 02507323 · $5.2610
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02528304
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Deferasirox (Type J) · DIN 02489902 · 180mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Deferasirox (Type J) · DIN 02489902 Manufacturer: Sandoz Canada Inc.; listing date 2021-07-30 Health Canada: Marketed since 2021-04-19 · brand SANDOZ DEFERASIROX (TYPE J) · ATC V03AC03 DEFERASIROX · form Tablet · route Oral · ingredients DEFERASIROX 180 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Deferasirox (Type J): Formulary list price $5.2610/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.2610 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97997 · Verify on the e-Formulary ↗ (DIN 02489902)

Source record
DIN 02489902: Sandoz Deferasirox (Type J) Raw flags: sec3=Y Item: 640000022; group id 700; item number 1728; lccId None; manufacturer id SDZ Source form: Tab; strength: 180mg Recorded listing: General benefit Source prices (unrounded): $5.2610; ministry $5.2610 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02489902 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97997
Interchangeable products
Apo-Deferasirox (Type J) · DIN 02485273 · $5.2610 Auro-Deferasirox (Type J) · DIN 02527782 · $5.2610 Jadenu · DIN 02452227 · $5.2610 Jamp Deferasirox (Type J) · DIN 02549840 · $5.2610 PMS-Deferasirox (Type J) · DIN 02528304 · $5.2610 Taro-Deferasirox (Type J) · DIN 02507323 · $5.2610
Shortage status: resolved shortage (ended 2025-04-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02489902
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Taro-Deferasirox (Type J) · DIN 02507323 · 180mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Taro-Deferasirox (Type J) · DIN 02507323 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2021-03-29 Health Canada: Marketed since 2021-03-04 · brand TARO-DEFERASIROX (TYPE J) · ATC V03AC03 DEFERASIROX · form Tablet · route Oral · ingredients DEFERASIROX 180 MG · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Taro-Deferasirox (Type J): Formulary list price $5.2610/unit (unit not stated in source; not the patient's cost)

Ministry pays: $5.2610 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99673 · Verify on the e-Formulary ↗ (DIN 02507323)

Source record
DIN 02507323: Taro-Deferasirox (Type J) Raw flags: sec3=Y Item: 640000022; group id 700; item number 1728; lccId None; manufacturer id TAR Source form: Tab; strength: 180mg Recorded listing: General benefit Source prices (unrounded): $5.2610; ministry $5.2610 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02507323 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99673
Interchangeable products
Apo-Deferasirox (Type J) · DIN 02485273 · $5.2610 Auro-Deferasirox (Type J) · DIN 02527782 · $5.2610 Jadenu · DIN 02452227 · $5.2610 Jamp Deferasirox (Type J) · DIN 02549840 · $5.2610 PMS-Deferasirox (Type J) · DIN 02528304 · $5.2610 Sandoz Deferasirox (Type J) · DIN 02489902 · $5.2610
Shortage status: resolved shortage (ended 2025-12-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02507323
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Deferasirox · DIN 02461552 · 250mg · tablet for suspension

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Deferasirox · DIN 02461552 Manufacturer: Apotex Inc.; listing date 2017-08-30 Health Canada: Marketed since 2017-06-29 · brand APO-DEFERASIROX · ATC V03AC03 DEFERASIROX · form Tablet for suspension · route Oral · ingredients DEFERASIROX 250 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Deferasirox: Formulary list price $10.4820/unit (unit not stated in source; not the patient's cost)

Ministry pays: $10.4820 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94919 · Verify on the e-Formulary ↗ (DIN 02461552)

Source record
DIN 02461552: Apo-Deferasirox Raw flags: sec3=Y Item: 640000014; group id 700; item number 1731; lccId None; manufacturer id APX Source form: Tab for Susp; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $10.4820; ministry $10.4820 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02461552 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94919
Interchangeable products
Exjade · DIN 02287439 · $10.4820 Sandoz Deferasirox · DIN 02464462 · $10.4820
Shortage status: resolved shortage (ended 2025-05-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02461552
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Exjade · DIN 02287439 · 250mg · tablet for suspension

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Exjade · DIN 02287439 Manufacturer: Novartis Pharma Canada Inc.; listing date 2017-08-30 Health Canada: Marketed since 2006-11-10 · brand EXJADE · ATC V03AC03 DEFERASIROX · form Tablet for suspension · route Oral · ingredients DEFERASIROX 250 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $10.4820 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77284 · Verify on the e-Formulary ↗ (DIN 02287439)

Source record
DIN 02287439: Exjade Raw flags: sec3=Y Item: 640000014; group id 700; item number 1731; lccId None; manufacturer id NOV Source form: Tab for Susp; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $23.0470; ministry $10.4820 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02287439 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77284
Interchangeable products
Apo-Deferasirox · DIN 02461552 · $10.4820 Sandoz Deferasirox · DIN 02464462 · $10.4820
Shortage status: anticipated shortage (last updated 2026-08-31); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02287439
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Sandoz Deferasirox · DIN 02464462 · 250mg · tablet for suspension

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Deferasirox · DIN 02464462 Manufacturer: Sandoz Canada Inc.; listing date 2017-08-30 Health Canada: Marketed since 2017-07-04 · brand SANDOZ DEFERASIROX · ATC V03AC03 DEFERASIROX · form Tablet for suspension · route Oral · ingredients DEFERASIROX 250 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Deferasirox: Formulary list price $10.4820/unit (unit not stated in source; not the patient's cost)

Ministry pays: $10.4820 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95260 · Verify on the e-Formulary ↗ (DIN 02464462)

Source record
DIN 02464462: Sandoz Deferasirox Raw flags: sec3=Y Item: 640000014; group id 700; item number 1731; lccId None; manufacturer id SDZ Source form: Tab for Susp; strength: 250mg Recorded listing: General benefit Source prices (unrounded): $10.4820; ministry $10.4820 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02464462 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=95260
Interchangeable products
Apo-Deferasirox · DIN 02461552 · $10.4820 Exjade · DIN 02287439 · $10.4820
Shortage status: resolved shortage (ended 2026-06-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02464462
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Deferasirox (Type J) · DIN 02485281 · 360mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Deferasirox (Type J) · DIN 02485281 Manufacturer: Apotex Inc.; listing date 2019-07-31 Health Canada: Marketed since 2019-05-29 · brand APO-DEFERASIROX (TYPE J) · ATC V03AC03 DEFERASIROX · form Tablet · route Oral · ingredients DEFERASIROX 360 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Deferasirox (Type J): Formulary list price $10.5228/unit (unit not stated in source; not the patient's cost)

Ministry pays: $10.5228 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97555 · Verify on the e-Formulary ↗ (DIN 02485281)

Source record
DIN 02485281: Apo-Deferasirox (Type J) Raw flags: sec3=Y Item: 640000023; group id 700; item number 1729; lccId None; manufacturer id APX Source form: Tab; strength: 360mg Recorded listing: General benefit Source prices (unrounded): $10.5228; ministry $10.5228 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02485281 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97555
Interchangeable products
Auro-Deferasirox (Type J) · DIN 02527790 · $10.5228 Jadenu · DIN 02452235 · $10.5228 Jamp Deferasirox (Type J) · DIN 02549859 · $10.5228 PMS-Deferasirox (Type J) · DIN 02528312 · $10.5228 Sandoz Deferasirox (Type J) · DIN 02489910 · $10.5228 Taro-Deferasirox (Type J) · DIN 02507331 · $10.5228
Shortage status: resolved shortage (ended 2024-08-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02485281
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Deferasirox (Type J) · DIN 02527790 · 360mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Deferasirox (Type J) · DIN 02527790 Manufacturer: Auro Pharma Inc.; listing date 2025-02-28 Health Canada: Marketed since 2024-08-14 · brand AURO-DEFERASIROX (TYPE J) · ATC V03AC03 DEFERASIROX · form Tablet · route Oral · ingredients DEFERASIROX 360 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Deferasirox (Type J): Formulary list price $10.5228/unit (unit not stated in source; not the patient's cost)

Ministry pays: $10.5228 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101697 · Verify on the e-Formulary ↗ (DIN 02527790)

Source record
DIN 02527790: Auro-Deferasirox (Type J) Raw flags: sec3=Y Item: 640000023; group id 700; item number 1729; lccId None; manufacturer id AUR Source form: Tab; strength: 360mg Recorded listing: General benefit Source prices (unrounded): $10.5228; ministry $10.5228 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02527790 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101697
Interchangeable products
Apo-Deferasirox (Type J) · DIN 02485281 · $10.5228 Jadenu · DIN 02452235 · $10.5228 Jamp Deferasirox (Type J) · DIN 02549859 · $10.5228 PMS-Deferasirox (Type J) · DIN 02528312 · $10.5228 Sandoz Deferasirox (Type J) · DIN 02489910 · $10.5228 Taro-Deferasirox (Type J) · DIN 02507331 · $10.5228
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02527790
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jadenu · DIN 02452235 · 360mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Jadenu · DIN 02452235 Manufacturer: Novartis Pharma Canada Inc.; listing date 2019-07-31 Health Canada: Marketed since 2016-03-24 · brand JADENU · ATC V03AC03 DEFERASIROX · form Tablet · route Oral · ingredients DEFERASIROX 360 MG · company Novartis pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $10.5228 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93866 · Verify on the e-Formulary ↗ (DIN 02452235)

Source record
DIN 02452235: Jadenu Raw flags: sec3=Y Item: 640000023; group id 700; item number 1729; lccId None; manufacturer id NOV Source form: Tab; strength: 360mg Recorded listing: General benefit Source prices (unrounded): $43.5730; ministry $10.5228 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02452235 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93866
Interchangeable products
Apo-Deferasirox (Type J) · DIN 02485281 · $10.5228 Auro-Deferasirox (Type J) · DIN 02527790 · $10.5228 Jamp Deferasirox (Type J) · DIN 02549859 · $10.5228 PMS-Deferasirox (Type J) · DIN 02528312 · $10.5228 Sandoz Deferasirox (Type J) · DIN 02489910 · $10.5228 Taro-Deferasirox (Type J) · DIN 02507331 · $10.5228
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02452235
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Deferasirox (Type J) · DIN 02549859 · 360mg · tablet

General benefitMarketed · checked 2026-09-02
Write on scriptno code needed
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp Deferasirox (Type J) · DIN 02549859 Manufacturer: Jamp Pharma Corporation; listing date 2026-07-31 Health Canada: Marketed since 2026-06-17 · brand JAMP DEFERASIROX (TYPE J) · ATC V03AC03 DEFERASIROX · form Tablet · route Oral · ingredients DEFERASIROX 360 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp Deferasirox (Type J): Formulary list price $10.5228/unit (unit not stated in source; not the patient's cost)

Ministry pays: $10.5228 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103867 · Verify on the e-Formulary ↗ (DIN 02549859)

Source record
DIN 02549859: Jamp Deferasirox (Type J) Raw flags: sec3=Y Item: 640000023; group id 700; item number 1729; lccId None; manufacturer id JPC Source form: Tab; strength: 360mg Recorded listing: General benefit Source prices (unrounded): $10.5228; ministry $10.5228 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02549859 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=103867
Interchangeable products
Apo-Deferasirox (Type J) · DIN 02485281 · $10.5228 Auro-Deferasirox (Type J) · DIN 02527790 · $10.5228 Jadenu · DIN 02452235 · $10.5228 PMS-Deferasirox (Type J) · DIN 02528312 · $10.5228 Sandoz Deferasirox (Type J) · DIN 02489910 · $10.5228 Taro-Deferasirox (Type J) · DIN 02507331 · $10.5228
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02549859
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (64:00 HEAVY METAL ANTAGONISTS) and how they are covered

Matched class: 64:00 HEAVY METAL ANTAGONISTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: PENICILLAMINE 64:00 HEAVY METAL ANTAGONISTS

DEFERIPRONE

· 2 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1000mg · Tab

PENICILLAMINE

· 1 products · General benefit · strengths: 250mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 64:00
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS EXJADE® (deferasirox) dispersible tablets is indicated for:  the management of chronic iron overload in patients with transfusion-dependent anemias aged 6 years or older.  the management of chronic iron overload in patients with transfusion-dependent anemias aged two to five who cannot be adequately treated with deferoxamine.  the treatment of chronic iron overload in patients with non-transfusion-dependent thalassemia syndromes aged 10 years and older. Therapy with EXJADE should be initiated and maintained by physicians experienced in the treatment of chronic iron overload due to blood transfusions. 1.1 Pediatrics Pediatrics (2 to 16 years of age): There are limited data available on the use of EXJADE in children aged 2 to 5 (see 7.1.3 Pediatrics). The overall exposure of EXJADE in young children (aged 2 to 5) was about 50% lower than in adults and this age group may require higher maintenance doses than are necessary in adults (see 4 DOSAGE AND ADMINISTRATION). 1.2 Geriatrics Geriatrics (≥ 65 years of age): Four hundred and thirty-one (431) patients ≥ 65 years of age have been studied i… https://pdf.hres.ca/dpd_pm/00067002.PDF PM date: NOV 10, 2006 Source product: EXJADE; DIN 02287420; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Prepare an Exceptional Access request

SADIE has its own form for many drugs; this checklist prepares the answers; the ministry decides. Open SADIE

Use this text in SADIE’s free-text fields or read from it on a Telephone Request Service call. Review marks do not indicate eligibility. Evidence stays in this page until you copy it; nothing entered here is sent or saved. Do not enter patient identifiers.

EAP Telephone Request Service: The TRS can be accessed by calling toll-free at 1-866-811-9893 or 416-327-8109 (Toronto area) between 8:30 a.m. and 5:00 p.m. Monday through Friday (except holidays) and selecting the TRS option. Source; updated September 15, 2026

EAP fax: In Ontario: 1-866-811-9908 or 416-327-7526 (Toronto area). Outside Ontario: 1-833-905-4260. Source; updated September 15, 2026

Posted turnaround and Telephone Request Service scope
Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days |
For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day.
Source; updated September 15, 2026

Deferasirox (Exjade)

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Prepare answers: See the ministry wording below; no separate indication heading is held.

Ministry criteria corpus 2025-01-01; page 71

Deferasirox Brand(s): Exjade DOSAGE FORM/ STRENGTH: 125 mg, 250 mg, 500 mg tablet Brand(s): Jadenu DOSAGE FORM/ STRENGTH: 90 mg, 180 mg, 360 mg tablet
Effective on January 31, 2022, deferasirox is available on the Ontario Drug Benefit formulary as a general benefit.

Prepared from the ministry's published criteria; eligibility is decided by the Exceptional Access Program.